From: The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote
Date | Pre-bronchodilator FEV1 L (%) | Pre-bronchodilator FVC L (%) | Pre-bronchodilator FEV1/FVC | Post-bronchodilator FEV1 L (%) | Post-bronchodilator FVC L (%) | Post-bronchodilator FEV1/FVC |
---|---|---|---|---|---|---|
Oct 2004 | 0.74 (21.0%) | 1.65 (37.2%) | 44.8 | 1.05 (29.8%) | 2.34 (52.7%) | 44.9 |
July 2005 | 1.15 (32.6%) | 2.14 (48.2%) | 53.6 | 1.24 (35.3%) | 2.24 (50.5%) | 55.4 |
May 2007 | 0.86 (24.9%) | 1.93 (44.1%) | 44.6 | 0.97 (28.0%) | 2.07 (47.4%) | 46.7 |
Dec 2008 | 1.04 (33.8%) | 2.28 (58.4%) | 45.5 | Not performed | Not performed | Not performed |
Aug 2009 | 0.96 (28.3%) | 2.51 (58.1%) | 38.4 | 1.10 (32.5%) | 2.69 (62.3%) | 41.0 |
April 2012 | 0.74 (22.4%) | 1.58 (37.4%) | 47.0 | Not performed | Not performed | Not performed |
Jan 2013 | 0.75 (23%) | 1.70 (41%) | 44.1 | Not performed | Not performed | Not performed |